Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 753-755

  Smith, Malcolm A ^a   Kang, Min H ^b   Reynolds, C Patrick ^b   Kurmasheva, Raushan T ^c   Alexander, Denise ^c   Billups, Catherine A ^d   Toretsky, Jeffrey A ^e   Houghton, Peter J ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

Arsenic trioxide; Developmental therapeutics; Ewing sarcoma; Preclinical testing

Indexed keywords

ARSENIC TRIOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; EWING SARCOMA; FEMALE; IC 50; MOUSE; NONHUMAN; PEDIATRIC PRECLINICAL TESTING PROGRAM; PRIORITY JOURNAL; SARCOMA CELL; TUMOR XENOGRAFT;

ANIMALS; ARSENICALS; BONE NEOPLASMS; CELL LINE, TUMOR; FEMALE; GROWTH INHIBITORS; MICE; MICE, SCID; OXIDES; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864949165     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23391     Document Type: Article

References (20)

1. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
2. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 3342-3347.
3. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328: 240-243.
4. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
5. Chen SJ, Zhou GB, Zhang XW, et al. From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011; 117: 6425-6437.
6. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 2011; 121: 148-160.
7. Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 2010; 107: 13432-13437.
8. Kang MH, Smith MA, Morton CL, et al. National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011; 56: 239-249.
9. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
10. Pettersson HM, Pietras A, Munksgaard Persson M, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 2009; 8: 160-170.
11. Ora I, Bondesson L, Jonsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000; 277: 179-185.
12. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043-1052.
13. Rego EM, He LZ, Warrell RP, Jr., et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 2000; 97: 10173-10178.
14. Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-244.
15. Fox E, Razzouk BI, Widemann BC, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 2008; 111: 566-573.
16. Sweeney CJ, Takimoto C, Wood L, et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol 2010; 66: 345-356.
17. Beauchamp E, Bulut G, Abaan O, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009; 284: 9074-9082.
18. Beer TM, Tangen CM, Nichols CR, et al. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006; 106: 2624-2629.
19. Kim KB, Bedikian AY, Camacho LH, et al. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005; 104: 1687-1692.
20. Vuky J, Yu R, Schwartz L, et al. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002; 20: 327-330.